Anteris Technologies Global (NASDAQ:AVR – Get Free Report) and OPKO Health (NASDAQ:OPK – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.
Insider and Institutional Ownership
64.6% of OPKO Health shares are owned by institutional investors. 4.0% of Anteris Technologies Global shares are owned by insiders. Comparatively, 49.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Anteris Technologies Global and OPKO Health”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anteris Technologies Global | $2.70 million | 51.55 | -$76.29 million | ($1.19) | -3.24 |
| OPKO Health | $642.07 million | 1.61 | -$53.22 million | ($0.25) | -5.38 |
OPKO Health has higher revenue and earnings than Anteris Technologies Global. OPKO Health is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Anteris Technologies Global and OPKO Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anteris Technologies Global | N/A | N/A | N/A |
| OPKO Health | -28.10% | -13.62% | -8.59% |
Analyst Ratings
This is a summary of current recommendations and price targets for Anteris Technologies Global and OPKO Health, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anteris Technologies Global | 1 | 0 | 4 | 0 | 2.60 |
| OPKO Health | 1 | 3 | 2 | 1 | 2.43 |
Anteris Technologies Global presently has a consensus target price of $16.50, suggesting a potential upside of 327.46%. OPKO Health has a consensus target price of $2.28, suggesting a potential upside of 69.76%. Given Anteris Technologies Global’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Anteris Technologies Global is more favorable than OPKO Health.
Summary
Anteris Technologies Global beats OPKO Health on 8 of the 14 factors compared between the two stocks.
About Anteris Technologies Global
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
About OPKO Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
